Fibroblast growth factor 23

From Wikipedia, the free encyclopedia
Jump to: navigation, search
FGF23
Protein FGF23 PDB 2p39.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases FGF23, ADHR, FGFN, HPDR2, HYPF, PHPTC, fibroblast growth factor 23
External IDs OMIM: 605380 MGI: 1891427 HomoloGene: 10771 GeneCards: 8074
RNA expression pattern
PBB GE FGF23 221166 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_020638

NM_022657

RefSeq (protein)

NP_065689.1

NP_073148.1

Location (UCSC) Chr 12: 4.37 – 4.38 Mb Chr 6: 127.07 – 127.08 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

Fibroblast growth factor 23 or FGF23 is a protein that in humans is encoded by the FGF23 gene.[1] FGF23 is a member of the fibroblast growth factor (FGF) family which is responsible for phosphate and vitamin D metabolism.[2][3]

Function[edit]

The main function of FGF23 seems to be regulation of phosphate concentration in plasma. FGF23 is secreted by osteocytes in response to elevated calcitriol. FGF23 acts on the kidneys, where it decreases the expression of NPT2, a sodium-phosphate cotransporter in the proximal tubule.[4] Thus, FGF23 decreases the reabsorption and increases excretion of phosphate. FGF23 may also suppress 1-alpha-hydroxylase, reducing its ability to activate vitamin D and subsequently impairing calcium absorption.[3]

Clinical significance[edit]

FGF23 is located on chromosome 12 and is composed of three exons. Mutations in FGF23 that render the protein resistant to proteolytic cleavage leads to increased activity of FGF23 and the renal phosphate loss found in the human disease autosomal dominant hypophosphatemic rickets. FGF23 is also overproduced by some types of tumors, such as the benign mesenchymal neoplasm Phosphaturic mesenchymal tumor causing tumor-induced osteomalacia, a paraneoplastic syndrome.[5] Loss of FGF23 activity is thought to lead to increased phosphate levels and the clinical syndrome of familial tumor calcinosis. This gene was identified by its mutations associated with autosomal dominant hypophosphatemic rickets.[6] Prior to discovery in 2000, it was hypothesized that a protein existed which performed the function of FGF23. This putative protein was known as phosphatonin.Two major types of effects • Direct Effects: • 1. Impairs sodium dependent phosphate transport in both intestinal and renal brush border membrane vesicles • 2. Inhibits production of calcitriol and stimulates breakdown of calcitriol • 3. Inhibits production/secretion of parathyroid

References[edit]

  1. ^ Yamashita T, Yoshioka M, Itoh N (October 2000). "Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain". Biochem. Biophys. Res. Commun. 277 (2): 494–8. doi:10.1006/bbrc.2000.3696. PMID 11032749. 
  2. ^ Fukumoto S (2008). "Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23". Intern. Med. 47 (5): 337–43. doi:10.2169/internalmedicine.47.0730. PMID 18310961. 
  3. ^ a b Perwad F (2007). "Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.". Am J Physiol Renal Physiol 293: F1577–83. doi:10.1152/ajprenal.00463.2006. PMID 17699549. 
  4. ^ Jüppner H (2011). "Phosphate and FGF-23". Kidney Int. Suppl. 79 (121): S24–7. doi:10.1038/ki.2011.27. PMC 3257051. PMID 21346724. 
  5. ^ Zadik Y, Nitzan DW (October 2011). "Tumor induced osteomalacia: A forgotten paraneoplastic syndrome?". Oral Oncol 48 (2): e9–10. doi:10.1016/j.oraloncology.2011.09.011. PMID 21985764. 
  6. ^ "Entrez Gene: FGF23 fibroblast growth factor 23". 

Further reading[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.